Nasdaq· Services-Advertising· Inc. DE· CIK 0001880613

DRCT

Direct Digital Holdings, Inc.
$0.9100 ▼ -39.74%
Prev close $1.51
Market cap$1.2M
12-mo target$32.00 (+3416.5%)
Insider Selling Cluster (4 insiders)High Impact Filing (7/10) Services
Snapshot
The big-picture read on DRCT right now — valuation, ownership and activity at a glance.
Market Cap
$1.2M
Cap Size
Nano Cap
Inst. Holders
4 funds
Inst. Value
$18.9K
Insider Activity
$0.00 buy / $9.0K sell
Insider Net $
-$9.0K
Social Sentiment
50° Neutral
SEC Reports
12
Price chart 30d -54.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 trading_halt
Halt Resumed: DRCT — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-02T17:01:19.000Z | Resumed 2026-10-02T17:06:19.000Z
Sep 2, 2026 Insider
Walker Mark D sold 500 shares
Chairman and CEO @ $1.90 ($950.00)
Sep 1, 2026 Insider
Walker Mark D sold 1,636 shares
Chairman and CEO @ $2.06 ($3.4K)
Aug 28, 2026 SEC
Direct Digital Holdings entered into the Thirteenth Amendment to its Term Loan Facility with Lafayette Square, securing
8-K — Impact 7/10
Aug 27, 2026 Insider
Walker Mark D disposed of 10,000 shares
Chairman and CEO
Aug 21, 2026 SEC
Direct Digital Holdings disclosed it is in multiple events of default under its term loan facility, including covenant b
8-K — Impact 8/10
Aug 12, 2026 SEC
Direct Digital Holdings (DRCT) reported Q2 2026 revenue of $7.8M (down 23% YoY) and a GAAP EPS of -$5.78, which beat the
PRESS-RELEASE — Impact 7/10
Jul 1, 2026 Event
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Class II: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim l
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
Apr 8, 2026BenchmarkMAINTAINSpeculative Buy 54%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20262420075%
Aug 1, 20262420075%
Jul 1, 20262420075%
Jun 1, 20262420075%
May 1, 20262420075%
Apr 1, 20262420075%
Mar 1, 20262420075%
Feb 1, 20262420075%
Price targets
Where 1 covering analysts think DRCT trades over the next 12 months.
$32.00 +3416.5% upside Strong Buy
Current$0.9100 Low$32.00 Median$32.00 High$32.00 1 analysts
$32.00$32.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
2 mentions 0 bullish 0 bearish 2 neutral
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 0 bullish, 8 bearish, 0 mixed, 4 neutral · avg impact 5.6/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
trading_halt
Halt Resumed: DRCT — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-02T17:01:19.000Z | Resumed 2026-10-02T17:06:19.000Z
Oct 2, 2026
trading_halt
Trading Halt: DRCT — LUDP (Volatility Trading Pause)
Direct Dig Hldgs Cl A Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 16, 2026
other
Orange 142 Launches Enrollment Edge, a New Resource Hub for Higher Education Marketers
Resource center combines practical tools, expert perspectives, and real-world strategies to help institutions attract and enroll more students AUSTIN,
Sep 14, 2026
short_volume
Short Volume: DRCT — 55.9% short (0.5M / 0.9M)
Short: 486,441 | Exempt: 1,642 | TRF Vol: 869,876 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
Clinical Trial
Study of ExoFlo for the Treatment of Perianal Fistulas
Phase Phase 2 — TERMINATED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-3.19$-3.19–$-3.1994.0%+64.6%0↑ 1↓$0.0B1
Next Q$-2.75$-2.75–$-2.7588.2%+68.2%0↑ 1↓$0.0B1
Current FY$-22.04$-22.04–$-22.0484.7%-39.3%0↑ 1↓$0.0B1
Next FY$-7.13$-7.13–$-7.1367.7%-38.4%0↑ 1↓$0.0B1
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-3.190—
7d ago$-9.005+5.815
30d ago$-9.005+5.815
60d ago$-9.005+5.815
90d ago$-9.005+5.815
Institutional ownership
Which big funds own DRCT (from quarterly 13F filings) and who is adding or trimming.
4 institutional holders with $18.9K total value (6,971 shares) as of 2026-Q2. Top holders: VANGUARD, BlackRock,, MORGAN.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
VANGUARD CAPITAL MANAGEMENT LLC6,905$18.7K99.1%—
BlackRock, Inc.33$90.000.5%—
MORGAN STANLEY26$70.000.4%—
Steward Partners Investment Advisory, LLC7$19.000.1%—
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$9.0K — $0.00 bought, $9.0K sold.
DateInsiderTitleTypeSharesPriceValue
Sep 2, 2026Walker Mark DChairman and CEOSELL500$1.90$950.00
Sep 1, 2026Walker Mark DChairman and CEOSELL1,636$2.06$3.4K
Aug 27, 2026Walker Mark DChairman and CEOCONVERT10,000——
Aug 27, 2026Walker Mark DChairman and CEOCONVERT10,000——
Jun 12, 2026Cohen RichardDirectorEXERCISE37——
Jun 12, 2026Leatherberry Antoinette ReneeDirectorEXERCISE37——
Jun 12, 2026Locke MistelleDirectorEXERCISE37——
Jun 12, 2026Locke MistelleDirectorSELL25$2.91$72.75
Jun 12, 2026Walker Mark DChairman and CEOSELL1,363$2.80$3.8K
Jun 12, 2026Cohen RichardDirectorSELL25$2.91$72.75
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DRCT.
Shares short
133,240
Settlement Sep 15, 2026
Change vs prior
+1501.8%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈16.6%
Estimate — not % of float
HaltedCodeReasonStatus
Oct 2, 2026LUDPVolatility PauseResumed
All DRCT filing & press-release reports (12)